CoChat
Sign Up
Cited by 398

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Intranasal drug delivery: An efficient and non-invasive route for systemic administration

Grassin-Delyle, Stanislas, Buenestado, Amparo, Naline, Emmanuel, Faisy, Christophe, Blouquit-Laye, Sabine, Couderc, Louis-Jean, Le Guen, Morgan, Fischler, Marc, Devillier, Philippe·2012·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2012.03.003
Open this paper in CoChat — free account

Abstract

Intranasal administration is a non-invasive route for drug delivery, which is widely used for the local treatment of rhinitis or nasal polyposis. Since drugs can be absorbed into the systemic circulation through the nasal mucosa, this route may also be used in a range of acute or chronic conditions requiring considerable systemic exposure. Indeed, it offers advantages such as ease of administration, rapid onset of action, and avoidance of first-pass metabolism, which consequently offers for example an interesting alternative to intravenous, subcutaneous, oral transmucosal, oral or rectal administration in the management of pain with opioids. Given these indisputable interests, fentanyl-containing formulations have been recently approved and marketed for the treatment of breakthrough cancer pain. This review will outline the relevant aspects of the therapeutic interest and limits of intranasal delivery of drugs, with a special focus on opioids, together with an in-depth discussion of the physiological characteristics of the nasal cavity as well as physicochemical properties (lipophilicity, molecular weight, ionisation) and pharmaceutical factors (absorption enhancers, devices for application) that should be considered for the development of nasal drugs.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2012.03.003

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 163

  1. 2011, Abstral (fentanyl sublingual tablets for breakthrough cancer pain), P T, 36, 2
  2. Agu, 2011, Differential expression of organic cation transporters in normal and polyps human nasal epithelium: implications for in vitro drug delivery studies, Int J Pharm, 406, 49, 10.1016/j.ijpharm.2010.12.037 · DOI
  3. Akerlund, 1993, Effect of oxymetazoline on nasal and sinus mucosal blood flow in the rabbit as measured with laser-Doppler flowmetry, Ann Otol Rhinol Laryngol, 102, 123, 10.1177/000348949310200209 · DOI
  4. Al Suleimani, 2007, Allergic rhinitis and its pharmacology, Pharmacol Ther, 114, 233, 10.1016/j.pharmthera.2007.01.012 · DOI
  5. Amidi, 2010, Chitosan-based delivery systems for protein therapeutics and antigens, Adv Drug Deliv Rev, 62, 59, 10.1016/j.addr.2009.11.009 · DOI
  6. Arora, 2002, Permeability issues in nasal drug delivery, Drug Discov Today, 7, 967, 10.1016/S1359-6446(02)02452-2 · DOI
  7. Baker, 2003, The effect of nitric oxide on the permeability of nasal epithelial cells from healthy and asthmatic donors, Med Sci Monit, 9, BR276
  8. Barton, 2005, Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting, J Emerg Med, 29, 265, 10.1016/j.jemermed.2005.03.007 · DOI
  9. Behl, 1998, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Adv Drug Deliv Rev, 29, 89, 10.1016/S0169-409X(97)00063-X · DOI
  10. Benninger, 2004, Techniques of intranasal steroid use, Otolaryngol Head Neck Surg, 130, 5, 10.1016/j.otohns.2003.10.007 · DOI
  11. Bernkop-Schnurch, 1998, The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins, J Control Release, 52, 1, 10.1016/S0168-3659(97)00204-6 · DOI
  12. Bonsmann, 2001, Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application, Allergy, 56, 532, 10.1034/j.1398-9995.2001.056006532.x · DOI
  13. Borland, 2007, A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department, Ann Emerg Med, 49, 335, 10.1016/j.annemergmed.2006.06.016 · DOI
  14. Borland, 2011, Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial, Emerg Med Australas, 23, 202, 10.1111/j.1742-6723.2011.01391.x · DOI
  15. Born, 2002, Sniffing neuropeptides: a transnasal approach to the human brain, Nat Neurosci, 5, 514, 10.1038/nn0602-849 · DOI · Paper page
  16. Bourget, 1995, Study of the bioequivalence of two controlled-release formulations of morphine, Int J Clin Pharmacol Ther, 33, 588
  17. Cass, 1999, Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers, Clin Pharmacokinet, 36, 1, 10.2165/00003088-199936001-00001 · DOI
  18. Charlton, 2007, Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies, J Control Release, 118, 225, 10.1016/j.jconrel.2006.12.014 · DOI
  19. Cheng, 2007, Computation of octanol–water partition coefficients by guiding an additive model with knowledge, J Chem Inf Model, 47, 2140, 10.1021/ci700257y · DOI
  20. Cho, 2010, Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron–cyclodextrin complex and carboxymethylcellulose for intranasal delivery, Int J Pharm, 400, 59, 10.1016/j.ijpharm.2010.08.030 · DOI
  21. Christrup, 2008, Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study, Clin Ther, 30, 469, 10.1016/j.clinthera.2008.03.001 · DOI
  22. Coda, 2003, Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers, Anesth Analg, 97, 117, 10.1213/01.ANE.0000066311.40978.4F · DOI
  23. Costantino, 2007, Intranasal delivery: physicochemical and therapeutic aspects, Int J Pharm, 337, 1, 10.1016/j.ijpharm.2007.03.025 · DOI
  24. Dale, 2002, Disposition of nasal, intravenous, and oral methadone in healthy volunteers, Clin Pharmacol Ther, 72, 536, 10.1067/mcp.2002.128386 · DOI
  25. Darwish, 2007, Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study, Clin Drug Investig, 27, 605, 10.2165/00044011-200727090-00002 · DOI
  26. Darwish, 2005, Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers, Clin Pharmacokinet, 44, 1279, 10.2165/00003088-200544120-00006 · DOI
  27. Darwish, 2006, Clin Ther, 28, 715, 10.1016/j.clinthera.2006.05.016 · DOI
  28. Davis, 2003, Absorption enhancers for nasal drug delivery, Clin Pharmacokinet, 42, 1107, 10.2165/00003088-200342130-00003 · DOI
  29. Davis, 2004, Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer, Am J Health Syst Pharm, 61, 261, 10.1093/ajhp/61.3.261 · DOI
  30. Davis, 2005, Bioavailability of intranasal butorphanol administered from a single-dose sprayer, Am J Health Syst Pharm, 62, 48, 10.1093/ajhp/62.1.48 · DOI
  31. Davis, 2004, Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis, Clin Drug Investig, 24, 633, 10.2165/00044011-200424110-00002 · DOI
  32. Davis, 2004, Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis, Pharmacotherapy, 24, 26, 10.1592/phco.24.1.26.34810 · DOI
  33. Devillier, 1988, Nasal response to substance P and methacholine in subjects with and without allergic rhinitis, Eur Respir J, 1, 356, 10.1183/09031936.93.01040356 · DOI
  34. Dhuria, 2009, Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system, J Pharmacol Exp Ther, 328, 312, 10.1124/jpet.108.145565 · DOI
  35. Ding, 2003, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annu Rev Pharmacol Toxicol, 43, 149, 10.1146/annurev.pharmtox.43.100901.140251 · DOI
  36. Dowley, 2001, The effect of inferior turbinate hypertrophy on nasal spray distribution to the middle meatus, Clin Otolaryngol Allied Sci, 26, 488, 10.1046/j.1365-2273.2001.00509.x · DOI
  37. Dowling, 2008, Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers, Ther Drug Monit, 30, 490, 10.1097/FTD.0b013e3181816214 · DOI
  38. Duan, 2010, New strategies to improve the intranasal absorption of insulin, Drug Discov Today, 15, 416, 10.1016/j.drudis.2010.03.011 · DOI
  39. Duquesnoy, 1998, Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration, Eur J Pharm Sci, 6, 99, 10.1016/S0928-0987(97)00073-0 · DOI
  40. Edman, 1992, Microspheres as a nasal delivery system for peptide drugs, J Control Release, 21, 165, 10.1016/0168-3659(92)90018-M · DOI
  41. Edwards, 2003, Hydromorphone transfer into breast milk after intranasal administration, Pharmacotherapy, 23, 153, 10.1592/phco.23.2.153.32081 · DOI
  42. Eriksen, 1989, The systemic availability of buprenorphine administered by nasal spray, J Pharm Pharmacol, 41, 803, 10.1111/j.2042-7158.1989.tb06374.x · DOI
  43. Fisher, 2010, Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan–poloxamer 188, Int J Clin Pharmacol Ther, 48, 138, 10.5414/CPP48138 · DOI
  44. Fitzgibbon, 2003, Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients, Pain, 106, 309, 10.1016/S0304-3959(03)00318-X · DOI
  45. Foo, 2007, The influence of spray properties on intranasal deposition, J Aerosol Med, 20, 495, 10.1089/jam.2007.0638 · DOI
  46. Foster, 2008, Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery, Ann Pharmacother, 42, 1380, 10.1345/aph.1L168 · DOI
  47. Gourlay, 1997, Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine, Clin Pharmacol Ther, 62, 453, 10.1016/S0009-9236(97)90124-7 · DOI
  48. Graff, 2003, P-Glycoprotein attenuates brain uptake of substrates after nasal instillation, Pharm Res, 20, 1225, 10.1023/A:1025053115583 · DOI
  49. Graff, 2005, Nasal drug administration: potential for targeted central nervous system delivery, J Pharm Sci, 94, 1187, 10.1002/jps.20318 · DOI
  50. Grape, 2010, Formulations of fentanyl for the management of pain, Drugs, 70, 57, 10.2165/11531740-000000000-00000 · DOI
  51. Greiff, 1994, Human nasal absorption of 51Cr-EDTA in smokers and control subjects, Clin Exp Allergy, 24, 1036, 10.1111/j.1365-2222.1994.tb02740.x · DOI
  52. Guthrie, 1999, Arterial/venous plasma nicotine concentrations following nicotine nasal spray, Eur J Clin Pharmacol, 55, 639, 10.1007/s002280050686 · DOI
  53. Gyi, 1994, Effect of halothane on cilia beat frequency of ciliated human respiratory epithelium in vitro, Br J Anaesth, 73, 507, 10.1093/bja/73.4.507 · DOI
  54. Haschke, 2010, Pharmacokinetics and pharmacodynamics of nasally delivered midazolam, Br J Clin Pharmacol, 69, 607, 10.1111/j.1365-2125.2010.03611.x · DOI
  55. Haugen, 2010, Assessment and classification of cancer breakthrough pain: a systematic literature review, Pain, 149, 476, 10.1016/j.pain.2010.02.035 · DOI
  56. Helmers, 1989, Comparison of intravenous and intranasal sufentanil absorption and sedation, Can J Anaesth, 36, 494, 10.1007/BF03005373 · DOI
  57. Henriksson, 1997, Expression of P-glycoprotein 170 in nasal mucosa may be increased with topical steroids, Am J Rhinol, 11, 317, 10.2500/105065897781446603 · DOI
  58. Henthorn, 1999, Active transport of fentanyl by the blood–brain barrier, J Pharmacol Exp Ther, 289, 1084, 10.1016/S0022-3565(24)38239-4 · DOI
  59. Hermens, 1987, The in vitro effect of morphine, fentanyl and sufentanil in ciliary beat frequency of human nasal epithelial tissue, Acta Pharm Technol, 33, 88
  60. Homer, 1998, An endoscopic photographic comparison of nasal drug delivery by aqueous spray, Clin Otolaryngol Allied Sci, 23, 560, 10.1046/j.1365-2273.1998.2360560.x · DOI
  61. Hybbinette, 1982, Effects of sympathomimetic agonists and antagonists on mucociliary activity, Acta Otolaryngol, 94, 121, 10.3109/00016488209128896 · DOI
  62. Hybbinette, 1982, Effects of the parasympathomimetic drug methacholine and its antagonist atropine on mucociliary activity, Acta Otolaryngol, 93, 465, 10.3109/00016488209130906 · DOI
  63. Illum, 1996, Nasal delivery. The use of animal models to predict performance in man, J Drug Target, 3, 427, 10.3109/10611869609015963 · DOI
  64. Illum, 2000, Transport of drugs from the nasal cavity to the central nervous system, Eur J Pharm Sci, 11, 1, 10.1016/S0928-0987(00)00087-7 · DOI · Paper page
  65. Illum, 2003, Nasal drug delivery—possibilities, problems and solutions, J Control Release, 87, 187, 10.1016/S0168-3659(02)00363-2 · DOI
  66. Illum, 2004, Is nose-to-brain transport of drugs in man a reality?, J Pharm Pharmacol, 56, 3, 10.1211/0022357022539 · DOI
  67. Illum, 1994, Chitosan as a novel nasal delivery system for peptide drugs, Pharm Res, 11, 1186, 10.1023/A:1018901302450 · DOI
  68. Illum, 1987, Bioadhesive microspheres as a potential nasal drug delivery system, Int J Pharm, 39, 189, 10.1016/0378-5173(87)90216-X · DOI
  69. Illum, 2002, Intranasal delivery of morphine, J Pharmacol Exp Ther, 301, 391, 10.1124/jpet.301.1.391 · DOI
  70. Ingels, 1992, Influence of sympathetic and parasympathetic substances in clinical concentrations on human nasal ciliary beat, Rhinology, 30, 149
  71. Inui, 2000, Cellular and molecular aspects of drug transport in the kidney, Kidney Int, 58, 944, 10.1046/j.1523-1755.2000.00251.x · DOI
  72. Irie, 1992, Enhancing effects of cyclodextrins on nasal absorption of insulin in rats, Int J Pharm, 84, 129, 10.1016/0378-5173(92)90053-5 · DOI
  73. Ishikawa, 2002, Insoluble powder formulation as an effective nasal drug delivery system, Pharm Res, 19, 1097, 10.1023/A:1019881706159 · DOI
  74. Kaasa, 2010, Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain, J Opioid Manag, 6, 17, 10.5055/jom.2010.0001 · DOI
  75. Kamel, 2004, Nasal and paranasal sinus changes after radiotherapy for nasopharyngeal carcinoma, Acta Otolaryngol, 124, 532, 10.1080/00016480410018106 · DOI
  76. Kanthakumar, 1994, Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin, Br J Pharmacol, 112, 493, 10.1111/j.1476-5381.1994.tb13100.x · DOI
  77. Karasulu, 2008, Permeation studies and histological examination of sheep nasal mucosa following administration of different nasal formulations with or without absorption enhancers, Drug Deliv, 15, 219, 10.1080/10717540802006377 · DOI
  78. Karl, 1992, Comparison of the safety and efficacy of intranasal midazolam or sufentanil for preinduction of anesthesia in pediatric patients, Anesthesiology, 76, 209, 10.1097/00000542-199202000-00009 · DOI
  79. Kato, 2008, Intestinal first-pass metabolism of CYP3A4 substrates, Drug Metab Pharmacokinet, 23, 87, 10.2133/dmpk.23.87 · DOI
  80. Koepsell, 1998, Organic cation transporters in intestine, kidney, liver, and brain, Annu Rev Physiol, 60, 243, 10.1146/annurev.physiol.60.1.243 · DOI
  81. Konrad, 1994, Mucociliary transport in ICU patients, Chest, 105, 237, 10.1378/chest.105.1.237 · DOI
  82. Kress, 2009, Clin Ther, 31, 1177, 10.1016/j.clinthera.2009.05.022 · DOI
  83. Krishnamoorthy, 1998, Prodrugs for nasal drug delivery, Adv Drug Deliv Rev, 29, 135, 10.1016/S0169-409X(97)00065-3 · DOI
  84. Kundoor, 2011, Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast, Pharm Res, 28, 1895, 10.1007/s11095-011-0417-6 · DOI
  85. Labiris, 2003, Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications, Br J Clin Pharmacol, 56, 588, 10.1046/j.1365-2125.2003.01892.x · DOI
  86. Lennernas, 2010, Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study, Palliat Med, 24, 286, 10.1177/0269216309356138 · DOI
  87. Leow, 1992, Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration, Ther Drug Monit, 14, 479, 10.1097/00007691-199212000-00008 · DOI
  88. Leow, 1992, Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer, Clin Pharmacol Ther, 52, 487, 10.1038/clpt.1992.176 · DOI · Paper page
  89. Lin, 2005, Transport of anti-allergic drugs across the passage cultured human nasal epithelial cell monolayer, Eur J Pharm Sci, 26, 203, 10.1016/j.ejps.2005.06.003 · DOI
  90. Liote, 1989, Role of mucus and cilia in nasal mucociliary clearance in healthy subjects, Am Rev Respir Dis, 140, 132, 10.1164/ajrccm/140.1.132 · DOI
  91. Loder, 2006, Post-marketing experience with an opioid nasal spray for migraine: lessons for the future, Cephalalgia, 26, 89, 10.1111/j.1468-2982.2005.00951.x · DOI
  92. Lofwall, 2012, Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers, J Clin Pharmacol, 52, 600, 10.1177/0091270011401620 · DOI
  93. Loimer, 1992, Nasal administration of naloxone for detection of opiate dependence, J Psychiatr Res, 26, 39, 10.1016/0022-3956(92)90014-F · DOI
  94. Loimer, 1994, Nasal administration of naloxone is as effective as the intravenous route in opiate addicts, Int J Addict, 29, 819, 10.3109/10826089409047912 · DOI
  95. Lou, 1999, Delayed irradiation effects on nasal epithelium in patients with nasopharyngeal carcinoma. An ultrastructural study, Ann Otol Rhinol Laryngol, 108, 474, 10.1177/000348949910800510 · DOI
  96. Mathieu, 2006, Intranasal sufentanil is effective for postoperative analgesia in adults, Can J Anaesth, 53, 60, 10.1007/BF03021528 · DOI
  97. Matsuyama, 2006, Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant, J Control Release, 110, 347, 10.1016/j.jconrel.2005.09.047 · DOI
  98. Matsuyama, 2006, Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent, J Control Release, 115, 183, 10.1016/j.jconrel.2006.08.004 · DOI
  99. McCarberg, 2007, The treatment of breakthrough pain, Pain Med, 8, S8, 10.1111/j.1526-4637.2006.00270.x · DOI
  100. McMartin, 1987, Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity, J Pharm Sci, 76, 535, 10.1002/jps.2600760709 · DOI
  101. Meijer, 1999, Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery, Nephrol Dial Transplant, 14, 1, 10.1093/ndt/14.suppl_4.1b · DOI
  102. Mercadante, 2009, A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial, Curr Med Res Opin, 25, 2805, 10.1185/03007990903336135 · DOI
  103. Mercadante, 2007, Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain, Br J Cancer, 96, 1828, 10.1038/sj.bjc.6603811 · DOI
  104. Middleton, 1993, Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects, Thorax, 48, 812, 10.1136/thx.48.8.812 · DOI
  105. Miller, 2008, Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study, Pharmacotherapy, 28, 875, 10.1592/phco.28.7.875 · DOI
  106. Mizuno, 2003, Impact of drug transporter studies on drug discovery and development, Pharmacol Rev, 55, 425, 10.1124/pr.55.3.1 · DOI
  107. Moksnes, 2008, Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?, Eur J Clin Pharmacol, 64, 497, 10.1007/s00228-007-0444-8 · DOI
  108. Morimoto, 1991, Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue, Pharm Res, 8, 1175, 10.1023/A:1015862603939 · DOI
  109. Morrison, 1990, Morphology of the human olfactory epithelium, J Comp Neurol, 297, 1, 10.1002/cne.902970102 · DOI
  110. Newman, 1987, Deposition pattern from a nasal pump spray, Rhinology, 25, 77
  111. Newman, 1994, The distribution of an intranasal insulin formulation in healthy volunteers: effect of different administration techniques, J Pharm Pharmacol, 46, 657, 10.1111/j.2042-7158.1994.tb03877.x · DOI
  112. O'Brien, 2012, Interactions between antidepressants and P-glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings, Br J Pharmacol, 165, 289, 10.1111/j.1476-5381.2011.01557.x · DOI
  113. Ohkubo, 1995, Human nasal mucosal carboxypeptidase: activity, location, and release, J Allergy Clin Immunol, 96, 924, 10.1016/S0091-6749(95)70230-X · DOI
  114. Ohkubo, 1994, Immunological localization of neuropeptide-degrading enzymes in the nasal mucosa, Rhinology, 32, 130
  115. Paech, 2003, A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study, Anaesthesia, 58, 740, 10.1046/j.1365-2044.2003.03286.x · DOI
  116. Parab, 1988, Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects, Biopharm Drug Dispos, 9, 187, 10.1002/bod.2510090207 · DOI
  117. Pavis, 2002, Pilot study of nasal morphine–chitosan for the relief of breakthrough pain in patients with cancer, J Pain Symptom Manage, 24, 598, 10.1016/S0885-3924(02)00522-5 · DOI
  118. Pereswetoff-Morath, 1998, Microspheres as nasal drug delivery systems, Adv Drug Deliv Rev, 29, 185, 10.1016/S0169-409X(97)00069-0 · DOI
  119. Portenoy, 2010, A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain, Pain, 151, 617, 10.1016/j.pain.2010.07.028 · DOI
  120. Portenoy, 1990, Breakthrough pain: definition, prevalence and characteristics, Pain, 41, 273, 10.1016/0304-3959(90)90004-W · DOI
  121. Raphael, 1996, Effects of 3 MAC of halothane, enflurane and isoflurane on cilia beat frequency of human nasal epithelium in vitro, Br J Anaesth, 76, 116, 10.1093/bja/76.1.116 · DOI
  122. Rauck, 2009, Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain, Curr Med Res Opin, 25, 2877, 10.1185/03007990903368310 · DOI
  123. Robbins, 1993, Stadol Nasal Spray—treatment for migraine?, Headache, 33, 220
  124. Rudy, 2004, A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers, Anesth Analg, 99, 1379, 10.1213/01.ANE.0000132927.47528.8B · DOI
  125. Sachdeva, 1993, Nasal mucociliary clearance & mucus pH in patients with diabetes mellitus, Indian J Med Res, 98, 265
  126. Salib, 2008, Mechanisms and mediators of nasal symptoms in non-allergic rhinitis, Clin Exp Allergy, 38, 393, 10.1111/j.1365-2222.2007.02926.x · DOI
  127. Salzman, 1995, Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers, Am J Physiol, 268, G361
  128. Scheibe, 2008, Intranasal administration of drugs, Arch Otolaryngol Head Neck Surg, 134, 643, 10.1001/archotol.134.6.643 · DOI
  129. Schwagmeier, 1995, Pharmacokinetics of intranasal alfentanil, J Clin Anesth, 7, 109, 10.1016/0952-8180(94)00023-W · DOI
  130. Selwyn, 1996, Effects of morphine on human nasal cilia beat frequency in vitro, Br J Anaesth, 76, 274, 10.1093/bja/76.2.274 · DOI
  131. Shao, 1992, Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations, Pharm Res, 9, 1157, 10.1023/A:1015847604654 · DOI
  132. Shyu, 1996, Pharmacokinetics of butorphanol nasal spray in patients with renal impairment, Br J Clin Pharmacol, 41, 397, 10.1046/j.1365-2125.1996.03327.x · DOI
  133. Shyu, 1993, Multiple-dose phase I study of transnasal butorphanol, Clin Pharmacol Ther, 54, 34, 10.1038/clpt.1993.106 · DOI
  134. Shyu, 1993, The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis, Eur J Clin Pharmacol, 45, 559, 10.1007/BF00315315 · DOI
  135. Simon, 1977, Measurement of transport in mucous membrane in the human nose with Cr-51-labeled resin beads, Acta Otolaryngol, 83, 378, 10.3109/00016487709128860 · DOI
  136. Soane, 1999, Evaluation of the clearance characteristics of bioadhesive systems in humans, Int J Pharm, 178, 55, 10.1016/S0378-5173(98)00367-6 · DOI
  137. Stanley, 1986, Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency, Thorax, 41, 519, 10.1136/thx.41.7.519 · DOI
  138. Stoker, 2008, Analgesic efficacy and safety of morphine–chitosan nasal solution in patients with moderate to severe pain following orthopedic surgery, Pain Med, 9, 3, 10.1111/j.1526-4637.2007.00300.x · DOI
  139. Striebel, 1993, Pharmacokinetics of intranasal Fentanyl, Schmerz, 7, 122, 10.1007/BF02527870 · DOI
  140. Stringer, 1995, Nasal mucociliary clearance after radiation therapy, Laryngoscope, 105, 380, 10.1288/00005537-199504000-00008 · DOI
  141. Surico, 2001, Impairment of nasal mucociliary clearance after radiotherapy for childhood head cancer, Head Neck, 23, 461, 10.1002/hed.1060 · DOI
  142. Tachibana, 2010, Predicting drug–drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein, Curr Drug Metab, 11, 762, 10.2174/138920010794328922 · DOI
  143. Takala, 1997, Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone, Acta Anaesthesiol Scand, 41, 309, 10.1111/j.1399-6576.1997.tb04684.x · DOI
  144. Tetko, 2005, Virtual computational chemistry laboratory—design and description, J Comput Aided Mol Des, 19, 453, 10.1007/s10822-005-8694-y · DOI
  145. Vachharajani, 1996, The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment, Clin Pharmacol Ther, 60, 283, 10.1016/S0009-9236(96)90055-7 · DOI
  146. Vachharajani, 1997, The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans, Biopharm Drug Dispos, 18, 191, 10.1002/(SICI)1099-081X(199704)18:3<191::AID-BDD9>3.0.CO;2-6 · DOI
  147. Vachharajani, 2002, A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration, Cephalalgia, 22, 282, 10.1046/j.1468-2982.2002.00359.x · DOI
  148. Veldhorst-Janssen, 2010, Clin Ther, 32, 1427, 10.1016/j.clinthera.2010.07.001 · DOI
  149. Verghese, 2008, The effect of intranasal administration of remifentanil on intubating conditions and airway response after sevoflurane induction of anesthesia in children, Anesth Analg, 107, 1176, 10.1213/ane.0b013e3181838e95 · DOI
  150. Wanner, 1996, Mucociliary clearance in the airways, Am J Respir Crit Care Med, 154, 1868, 10.1164/ajrccm.154.6.8970383 · DOI
  151. Washington, 2000, Determination of baseline human nasal pH and the effect of intranasally administered buffers, Int J Pharm, 198, 139, 10.1016/S0378-5173(99)00442-1 · DOI
  152. Watts, 2009, PecSys: in situ gelling system for optimised nasal drug delivery, Expert Opin Drug Deliv, 6, 543, 10.1517/17425240902939135 · DOI
  153. Wermeling, 2005, Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 27, 430, 10.1016/j.clinthera.2005.04.002 · DOI
  154. Wermeling, 2001, Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration, J Clin Pharmacol, 41, 1225, 10.1177/00912700122012779 · DOI
  155. Wermeling, 2005, Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps, J Clin Pharmacol, 45, 969, 10.1177/0091270005278057 · DOI
  156. Westerling, 1995, Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions, Ther Drug Monit, 17, 287, 10.1097/00007691-199506000-00013 · DOI
  157. Wioland, 2000, CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa, J Histochem Cytochem, 48, 1215, 10.1177/002215540004800905 · DOI
  158. Yang, 2001, Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir, J Pharm Sci, 90, 617, 10.1002/1520-6017(200105)90:5<617::AID-JPS1018>3.0.CO;2-5 · DOI
  159. Zaki, 2006, Rapid-onset intranasal delivery of metoclopramide hydrochloride. Part I. Influence of formulation variables on drug absorption in anesthetized rats, Int J Pharm, 327, 89, 10.1016/j.ijpharm.2006.07.040 · DOI
  160. Zedie, 1996, Comparison of intranasal midazolam and sufentanil premedication in pediatric outpatients, Clin Pharmacol Ther, 59, 341, 10.1016/S0009-9236(96)80012-9 · DOI
  161. Zeppetella, 2000, An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study, J Pain Symptom Manage, 20, 253, 10.1016/S0885-3924(00)00180-9 · DOI
  162. Zeppetella, 2006, Opioids for the management of breakthrough (episodic) pain in cancer patients, Cochrane Database Syst Rev, CD004311
  163. Zhang, 2005, Expression of cytochrome p450 and other biotransformation genes in fetal and adult human nasal mucosa, Drug Metab Dispos, 33, 1423, 10.1124/dmd.105.005769 · DOI

Cited by

Sorted by citations

See all 398

Metadata

Authors
Grassin-Delyle, S., Buenestado, A., Naline, E., Faisy, C., Blouquit-Laye, S., Couderc, L.-J., Le Guen, M., Fischler, M., & Devillier, P.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2012-06
Volume
134
Issue
3
Pages
366-379
ISSN
0163-7258
DOI
10.1016/j.pharmthera.2012.03.003
Cited by
398
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review